{"Title":"Athenex","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"437","Founded":"","Address":"","Phone":"(716) 427-2950","Web_address":"http://www.athenex.com","Market_cup":"$662.98mil","Revenues":"$20.5 mil (last 12 months)","Net_income":"$-118.1 mil (last 12 months)","Symbol":"ATNX","Exchange":"NASDAQ","Shares":"6.0","Price_range":"$11.00 - $11.00","Est_volume":"$66.0 mil","Manager":"Credit Suisse/ Deutsche Bank Securities/ J.P. Morgan","CO_managers":"ICBC International","Exp_to_trade":"6/14/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We have generated our clinical product candidates through our Orascovery and Src Kinase Inhibition research platforms, which are based on our understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively."}